| Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine LR Baden, HM El Sahly, B Essink, K Kotloff, S Frey, R Novak, D Diemert, ... New England journal of medicine 384 (5), 403-416, 2021 | 9985 | 2021 |
| Persistence and evolution of SARS-CoV-2 in an immunocompromised host B Choi, MC Choudhary, J Regan, JA Sparks, RF Padera, X Qiu, ... New England Journal of Medicine 383 (23), 2291-2293, 2020 | 1137 | 2020 |
| SARS-CoV-2 viral load is associated with increased disease severity and mortality J Fajnzylber, J Regan, K Coxen, H Corry, C Wong, A Rosenthal, D Worrall, ... Nature communications 11 (1), 5493, 2020 | 850 | 2020 |
| Diagnostic testing for severe acute respiratory syndrome–related coronavirus 2: a narrative review MP Cheng, J Papenburg, M Desjardins, S Kanjilal, C Quach, M Libman, ... Annals of internal medicine 172 (11), 726-734, 2020 | 818 | 2020 |
| Efficacy of the mRNA-1273 SARS-CoV-2 vaccine at completion of blinded phase HM El Sahly, LR Baden, B Essink, S Doblecki-Lewis, JM Martin, ... New England Journal of Medicine 385 (19), 1774-1785, 2021 | 517 | 2021 |
| Circulating severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine antigen detected in the plasma of mRNA-1273 vaccine recipients AF Ogata, CA Cheng, M Desjardins, Y Senussi, AC Sherman, M Powell, ... Clinical Infectious Diseases 74 (4), 715-718, 2022 | 228 | 2022 |
| Serodiagnostics for Severe Acute Respiratory Syndrome–Related Coronavirus 2: A Narrative Review MP Cheng, CP Yansouni, NE Basta, M Desjardins, S Kanjilal, K Paquette, ... Annals of internal medicine 173 (6), 450-460, 2020 | 172 | 2020 |
| Antinucleocapsid antibodies after SARS-CoV-2 infection in the blinded phase of the randomized, placebo-controlled mRNA-1273 COVID-19 vaccine efficacy clinical trial D Follmann, HE Janes, OD Buhule, H Zhou, B Girard, K Marks, K Kotloff, ... Annals of internal medicine 175 (9), 1258-1265, 2022 | 71 | 2022 |
| Structural basis for continued antibody evasion by the SARS-CoV-2 receptor binding domain KG Nabel, SA Clark, S Shankar, J Pan, LE Clark, P Yang, A Coscia, ... Science 375 (6578), eabl6251, 2021 | 69 | 2021 |
| Inflammasome activation in neutrophils of patients with severe COVID-19 K Aymonnier, J Ng, LE Fredenburgh, K Zambrano-Vera, P Münzer, ... Blood Advances 6 (7), 2001-2013, 2022 | 64 | 2022 |
| Protective heterologous T cell immunity in COVID-19 induced by the trivalent MMR and Tdap vaccine antigens V Mysore, X Cullere, ML Settles, X Ji, MW Kattan, M Desjardins, ... Med 2 (9), 1050-1071. e7, 2021 | 38 | 2021 |
| Activity of mRNA COVID-19 vaccines in patients with lymphoid malignancies JL Crombie, AC Sherman, CA Cheng, CE Ryan, R Zon, M Desjardins, ... Blood Advances 5 (16), 3062-3065, 2021 | 22 | 2021 |
| Delirium and inflammation in older adults hospitalized for COVID-19: a cohort study MF Forget, S Del Degan, J Leblanc, R Tannous, M Desjardins, M Durand, ... Clinical interventions in aging, 1223-1230, 2021 | 19 | 2021 |
| Anti-nucleocapsid antibodies following SARS-CoV-2 infection in the blinded phase of the mRNA-1273 Covid-19 vaccine efficacy clinical trial D Follmann, HE Janes, OD Buhule, H Zhou, B Girard, K Marks, K Kotloff, ... medRxiv, 2022.04. 18.22271936, 2022 | 15 | 2022 |
| La maladie à coronavirus (COVID-19): portrait des connaissances actuelles A Lapierre, G Fontaine, PL Tremblay, MA Maheu-Cadotte, M Desjardins Soins d’urgence 1 (1), 13-19, 2020 | 12 | 2020 |
| Severe acute respiratory syndrome coronavirus 2 messenger RNA vaccines in allogeneic hematopoietic stem cell transplant recipients: immunogenicity and reactogenicity AC Sherman, M Desjardins, CA Cheng, B Bausk, N Izaguirre, G Zhou, ... Clinical Infectious Diseases 75 (1), e920-e923, 2022 | 11 | 2022 |
| Respiratory infections: Clinical characteristics of pediatric pertussis cases, Quebec 2015–2017 M Desjardins, D Iachimov, S Mousseau, P Doyon-Plourde, N Brousseau, ... Canada Communicable Disease Report 44 (9), 190, 2018 | 11 | 2018 |
| Clinical and demographic factors associated with COVID-19, severe COVID-19, and SARS-CoV-2 infection in adults: a secondary cross-protocol analysis of 4 randomized clinical trials DA Theodore, AR Branche, L Zhang, DS Graciaa, M Choudhary, ... JAMA network open 6 (7), e2323349-e2323349, 2023 | 9 | 2023 |
| The effect of vaccine type and SARS-CoV-2 lineage on commercial SARS-CoV-2 serologic and pseudotype neutralization assays in mRNA vaccine recipients NV Tolan, AC Sherman, G Zhou, KG Nabel, M Desjardins, S Melanson, ... Microbiology spectrum 10 (2), e00211-22, 2022 | 9 | 2022 |
| Vaccine-induced severe acute respiratory syndrome coronavirus 2 antibody response and the path to accelerating development (determining a correlate of protection) AC Sherman, M Desjardins, LR Baden Clinics in Laboratory Medicine 42 (1), 111-128, 2022 | 9 | 2022 |
